Patent ductus arteriosus
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
premature very low birth weight infants: prophylactic therapy
intravenous indomethacin
The cut-off of very low birth weight varies between centers, but is usually <1300 g or <1000 g.
The treatment is based on the premise that treating a patent ductus arteriosus (PDA) in very low birth weight premature infants will prevent the clinical sequelae of a hemodynamically significant shunt better than waiting for the PDA to become clinically evident.
Treatment can be given at day 0 of life, before clinical evidence of a PDA becomes evident. The first dose is usually started within the first 12 hours of life.
Evidence shows that while prophylactic indomethacin might increase ductal closure and decrease the incidence of intraventricular hemorrhage, there are few other short-term or long-term benefits.[48]Fowlie PW, Davis PG. Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2003 Nov;88(6):F464-6. http://fn.bmj.com/cgi/content/full/88/6/F464 http://www.ncbi.nlm.nih.gov/pubmed/14602691?tool=bestpractice.com [53]Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2010;(7):CD000174. http://www.ncbi.nlm.nih.gov/pubmed/20614421?tool=bestpractice.com [54]Mitra S, Gardner CE, MacLellan A, et al. Prophylactic cyclo-oxygenase inhibitor drugs for the prevention of morbidity and mortality in preterm infants: a network meta-analysis. Cochrane Database Syst Rev. 2022 Apr 1;(4):CD013846. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013846.pub2/full http://www.ncbi.nlm.nih.gov/pubmed/35363893?tool=bestpractice.com [55]Mitra S, de Boode WP, Weisz DE, et al. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2023 Apr 11;4(4):CD013588. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013588.pub2/full http://www.ncbi.nlm.nih.gov/pubmed/37039501?tool=bestpractice.com
Infants being treated with indomethacin must have electrolytes, creatinine, urine output, and platelets monitored regularly during administration. Feeds are withheld.
Complications can include necrotizing enterocolitis, bleeding, or renal dysfunction.[56]Little DC, Pratt TC, Blalock SE, et al. Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment. J Pediatr Surg. 2003 Mar;38(3):492-6. http://www.ncbi.nlm.nih.gov/pubmed/12632374?tool=bestpractice.com [57]Ohlsson A, Bottu J, Govan J, et al. Effect of indomethacin on cerebral blood flow velocities in very low birth weight neonates with a patent ductus arteriosus. Dev Pharmacol Ther. 1993;20(1-2):100-6. http://www.ncbi.nlm.nih.gov/pubmed/7924757?tool=bestpractice.com
If the first course of ibuprofen or indomethacin is unsuccessful, a second course is usually given prior to consideration of procedural closure.[59]Canadian Paediatric Society. Management of the patent ductus arteriosus in preterm infants. Feb 2022 [internet publication]. https://cps.ca/en/documents/position/patent-ductus-arteriosus
Primary options
indomethacin: 0.1 mg/kg intravenously once daily for 3 days
premature infants (<32 weeks)
ibuprofen or indomethacin
Cyclooxygenase inhibitors (e.g., nonsteroidal anti-inflammatory drugs) inhibit prostaglandins, and have been shown to be effective in ductal closure in preterm infants.[8]Gersony WM, Peckham GJ, Ellison RC, et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr. 1983 Jun;102(6):895-906. http://www.ncbi.nlm.nih.gov/pubmed/6343572?tool=bestpractice.com Treatment is given in the first few days of life after a patent ductus arteriosus (PDA) has become clinically evident or has been diagnosed by echo.
Indomethacin was previously the standard of care; however, ibuprofen is now largely considered the pharmacotherapy of choice due to its similar efficacy but significantly better safety profile.[58]Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2020 Feb 11;2:CD003481. https://www.doi.org/10.1002/14651858.CD003481.pub8 http://www.ncbi.nlm.nih.gov/pubmed/32045960?tool=bestpractice.com [59]Canadian Paediatric Society. Management of the patent ductus arteriosus in preterm infants. Feb 2022 [internet publication]. https://cps.ca/en/documents/position/patent-ductus-arteriosus [60]Al-Turkait A, Szatkowski L, Choonara I, et al. Management of patent ductus arteriosus in very preterm infants in England and Wales: a retrospective cohort study. BMJ Paediatr Open. 2022 Mar;6(1):e001424. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928285 http://www.ncbi.nlm.nih.gov/pubmed/36053632?tool=bestpractice.com [61]Backes CH, Hill KD, Shelton EL, et al. Patent ductus arteriosus: a contemporary perspective for the pediatric and adult cardiac care provider. J Am Heart Assoc. 2022 Sep 6;11(17):e025784. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496432 http://www.ncbi.nlm.nih.gov/pubmed/36056734?tool=bestpractice.com
One Cochrane review comparing both oral and intravenous ibuprofen with indomethacin found a decreased risk of necrotizing enterocolitis and transient kidney injury in patients treated with ibuprofen, with similar effectiveness between interventions.[58]Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2020 Feb 11;2:CD003481.
https://www.doi.org/10.1002/14651858.CD003481.pub8
http://www.ncbi.nlm.nih.gov/pubmed/32045960?tool=bestpractice.com
[ ]
How does ibuprofen compare with standard indomethacin therapy for preterm/low birth weight infants with patent ductus arteriosus (PDA)?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.2393/fullShow me the answer Both ibuprofen and indomethacin have been shown to reduce the risk of severe intraventricular hemorrhage, although indomethacin appears to be more effective, hence why it is used in preference to ibuprofen as a prophylactic treatment in very low birth weight babies.[55]Mitra S, de Boode WP, Weisz DE, et al. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2023 Apr 11;4(4):CD013588.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013588.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/37039501?tool=bestpractice.com
Studies suggest that high-dose ibuprofen may increase the likelihood of PDA closure compared to standard-dose ibuprofen.[55]Mitra S, de Boode WP, Weisz DE, et al. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2023 Apr 11;4(4):CD013588.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013588.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/37039501?tool=bestpractice.com
[58]Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2020 Feb 11;2:CD003481.
https://www.doi.org/10.1002/14651858.CD003481.pub8
http://www.ncbi.nlm.nih.gov/pubmed/32045960?tool=bestpractice.com
[62]Mitra S, Florez ID, Tamayo ME, et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA. 2018 Mar 27;319(12):1221-1238.
https://jamanetwork.com/journals/jama/article-abstract/2676110
http://www.ncbi.nlm.nih.gov/pubmed/29584842?tool=bestpractice.com
[63]Yeung T, Shahroor M, Jain A, et al. Efficacy and safety of high versus standard dose ibuprofen for patent ductus arteriosus treatment in preterm infants: A systematic review and meta-analysis. J Neonatal Perinatal Med. 2022;15(3):501-10.
http://www.ncbi.nlm.nih.gov/pubmed/35404294?tool=bestpractice.com
High-dose ibuprofen may therefore be considered the preferred dosage; however, significant caution should be exercised in preterm infants younger than 26 weeks due to a lack of data in this age group.[59]Canadian Paediatric Society. Management of the patent ductus arteriosus in preterm infants. Feb 2022 [internet publication].
https://cps.ca/en/documents/position/patent-ductus-arteriosus
Studies have reported that oral ibuprofen is as effective as intravenous ibuprofen, with no significant difference in morbidity demonstrated.[58]Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2020 Feb 11;2:CD003481.
https://www.doi.org/10.1002/14651858.CD003481.pub8
http://www.ncbi.nlm.nih.gov/pubmed/32045960?tool=bestpractice.com
[64]Neumann R, Schulzke SM, Bührer C. Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology. 2012;102(1):9-15.
http://www.ncbi.nlm.nih.gov/pubmed/22414850?tool=bestpractice.com
[65]Erdeve O, Yurttutan S, Altug N, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2012 Jul;97(4):F279-83.
http://www.ncbi.nlm.nih.gov/pubmed/22147286?tool=bestpractice.com
Treatment with indomethacin has shown to be successful in closing symptomatic PDAs compared with placebo.[8]Gersony WM, Peckham GJ, Ellison RC, et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr. 1983 Jun;102(6):895-906. http://www.ncbi.nlm.nih.gov/pubmed/6343572?tool=bestpractice.com [66]Evans P, O'Reilly D, Flyer JN, et al. Indomethacin for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2021 Jan 15;1:CD013133. https://www.doi.org/10.1002/14651858.CD013133.pub2 http://www.ncbi.nlm.nih.gov/pubmed/33448032?tool=bestpractice.com While some centers practice a prolonged course of indomethacin (>4 and usually 7 doses), no significant difference has been shown in successful PDA closure, need for retreatment, need for surgical ligation, or such outcomes as mortality and the incidence of comorbidities such as chronic lung disease or necrotizing enterocolitis with this longer regimen.[67]Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2007;(1):CD003480. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003480.pub3/full http://www.ncbi.nlm.nih.gov/pubmed/17443527?tool=bestpractice.com
Infants being treated with ibuprofen and indomethacin must have electrolytes, creatinine, urine output and platelets followed regularly during administration. Feeds are withheld. B-type natriuretic peptide-guided treatment has been shown to reduce the number of primary indomethacin doses in infants with PDA.[68]Attridge JT, Kaufman DA, Lim DS, et al. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2009 May;94(3):F178-82. http://www.ncbi.nlm.nih.gov/pubmed/18981033?tool=bestpractice.com Complications with indomethacin can include necrotizing enterocolitis, bleeding, or renal dysfunction.[56]Little DC, Pratt TC, Blalock SE, et al. Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment. J Pediatr Surg. 2003 Mar;38(3):492-6. http://www.ncbi.nlm.nih.gov/pubmed/12632374?tool=bestpractice.com [57]Ohlsson A, Bottu J, Govan J, et al. Effect of indomethacin on cerebral blood flow velocities in very low birth weight neonates with a patent ductus arteriosus. Dev Pharmacol Ther. 1993;20(1-2):100-6. http://www.ncbi.nlm.nih.gov/pubmed/7924757?tool=bestpractice.com
If the first course of ibuprofen or indomethacin is unsuccessful, a second course is usually given prior to consideration of procedural closure.[59]Canadian Paediatric Society. Management of the patent ductus arteriosus in preterm infants. Feb 2022 [internet publication]. https://cps.ca/en/documents/position/patent-ductus-arteriosus
Primary options
ibuprofen lysine: standard-dose regimen: 10 mg/kg intravenously as a loading dose, followed by 5 mg/kg every 24 hours for 2 doses; high-dose regimen: 15-20 mg/kg intravenously as a loading dose, followed by 7.5 to 10 mg/kg every 24 hours for 2 doses
Secondary options
indomethacin: infants <48 hours of age: 0.2 mg/kg intravenously as a loading dose, followed by 0.1 mg/kg every 12-24 hours for 2 doses; infants 2-7 days of age: 0.2 mg/kg intravenously every 12-24 hours for 3 doses; infants >7 days of age: 0.2 mg/kg intravenously as a loading dose, followed by 0.25 mg/kg every 12-24 hours for 2 doses
OR
ibuprofen: standard-dose regimen: 10 mg/kg orally as a loading dose, followed by 5 mg/kg every 24 hours for 2 doses; high-dose regimen: 15-20 mg/kg orally as a loading dose, followed by 7.5 to 10 mg/kg every 24 hours for 2 doses
conservative management
Conservative management may be considered as an alternative to medical treatment in certain circumstances.
The Canadian Paediatric Society makes a conditional recommendation for conservative management of symptomatic PDA in the first 1-2 weeks post-birth.[59]Canadian Paediatric Society. Management of the patent ductus arteriosus in preterm infants. Feb 2022 [internet publication]. https://cps.ca/en/documents/position/patent-ductus-arteriosus
One systematic review and meta-analysis found no significant differences in morbidity or mortality in clinical trials assessing conservative management compared to pharmacologic or surgical treatment in preterm infants.[69]Hundscheid T, Jansen EJS, Onland W, et al. Conservative management of patent ductus arteriosus in preterm infants - A systematic review and meta-analyses assessing differences in outcome measures between randomized controlled trials and cohort studies. Front Pediatr. 2021;9:626261. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946967 http://www.ncbi.nlm.nih.gov/pubmed/33718300?tool=bestpractice.com One Cochrane review had similar findings, with early (<7 days old) or very early (<72 hours old) empiric treatment of PDA no more effective than conservative management in mortality or morbidity outcomes (including development of chronic lung disease, necrotizing enterocolitis, severe intraventricular hemorrhage, or neurodevelopmental abnormalities).[70]Mitra S, Scrivens A, von Kursell AM, et al. Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants. Cochrane Database Syst Rev. 2020 Dec 10;12:CD013278. https://www.doi.org/10.1002/14651858.CD013278.pub2 http://www.ncbi.nlm.nih.gov/pubmed/33301630?tool=bestpractice.com One multicenter randomized controlled trial found that expectant management for PDA in extremely premature infants was noninferior to early ibuprofen treatment with respect to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks’ postmenstrual age.[71]Hundscheid T, Onland W, Kooi EMW, et al. Expectant management or early ibuprofen for patent ductus arteriosus. N Engl J Med. 2023 Mar 16;388(11):980-90. https://www.nejm.org/doi/10.1056/NEJMoa2207418 http://www.ncbi.nlm.nih.gov/pubmed/36477458?tool=bestpractice.com
Conservative management in preterm infants may involve diuretic therapy, increasing positive airway pressures, and fluid restriction, although these approaches have not been systematically assessed in clinical trials.[59]Canadian Paediatric Society. Management of the patent ductus arteriosus in preterm infants. Feb 2022 [internet publication]. https://cps.ca/en/documents/position/patent-ductus-arteriosus [61]Backes CH, Hill KD, Shelton EL, et al. Patent ductus arteriosus: a contemporary perspective for the pediatric and adult cardiac care provider. J Am Heart Assoc. 2022 Sep 6;11(17):e025784. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496432 http://www.ncbi.nlm.nih.gov/pubmed/36056734?tool=bestpractice.com [72]Vanhaesebrouck S, Zonnenberg I, Vandervoort P, et al. Conservative treatment for patent ductus arteriosus in the preterm. Arch Dis Child Fetal Neonatal Ed. 2007 Jul;92(4):F244-7. http://www.ncbi.nlm.nih.gov/pubmed/17213270?tool=bestpractice.com [73]Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2014;(12):CD000503. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000503.pub3/full http://www.ncbi.nlm.nih.gov/pubmed/25473815?tool=bestpractice.com
Significant caution should be exercised if considering conservative management in high-risk preterm infants (e.g., those younger than 26 weeks).[59]Canadian Paediatric Society. Management of the patent ductus arteriosus in preterm infants. Feb 2022 [internet publication]. https://cps.ca/en/documents/position/patent-ductus-arteriosus
surgical ligation
Surgical ligation is usually considered after medical therapy has failed to result in ductal closure or is contraindicated.[59]Canadian Paediatric Society. Management of the patent ductus arteriosus in preterm infants. Feb 2022 [internet publication].
https://cps.ca/en/documents/position/patent-ductus-arteriosus
It can be performed on premature infants as small as 600 g. Surgical ligation of the duct generally has very high success rates with low associated morbidity.[75]Koehne PS, Bein G, Alexi-Meskhishvili V, et al. Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment. J Perinat Med. 2001;29(4):327-34.
http://www.ncbi.nlm.nih.gov/pubmed/11565202?tool=bestpractice.com
[77]Lee LC, Tillet A, Tulloh R. Outcome following patent ductus arteriosus ligation in premature infants: a retrospective cohort analysis. BMC Pediatr. 2006 May 11;6:15.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16689986
http://www.ncbi.nlm.nih.gov/pubmed/16689986?tool=bestpractice.com
Complications are rare and include recanalization of the duct, pneumothorax, effusion, hemorrhage, and wound infection.[76]Demir T, Oztunc F, Cetin G, et al. Patency or recanalization of the arterial duct after surgical double ligation and transfixion. Cardiol Young. 2007 Feb;17(1):48-50.
http://www.ncbi.nlm.nih.gov/pubmed/17184567?tool=bestpractice.com
While one study did show a relatively high late mortality in preterm infants, this was felt to be related to the high risk inherent in this population, rather than to the surgery itself.[77]Lee LC, Tillet A, Tulloh R. Outcome following patent ductus arteriosus ligation in premature infants: a retrospective cohort analysis. BMC Pediatr. 2006 May 11;6:15.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16689986
http://www.ncbi.nlm.nih.gov/pubmed/16689986?tool=bestpractice.com
There has been some inquiry into the favorability of surgical ligation as first-line management in this population.[78]Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2013;(3):CD003951.
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003951.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/23543527?tool=bestpractice.com
[79]Clyman R, Cassady G, Kirklin JK, et al. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Ped. 2009 Jun;154(6):873-6.
http://www.ncbi.nlm.nih.gov/pubmed/19324366?tool=bestpractice.com
However, there are currently limited data to allow for adequate comparison of the two treatment approaches.[78]Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2013;(3):CD003951.
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003951.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/23543527?tool=bestpractice.com
[ ]
In preterm infants with symptomatic patent ductus arteriosus, what are the benefits and harms of surgical compared with medical treatment with indomethacin?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.632/fullShow me the answer One review suggested that there may be little benefit to prophylactic surgical ligation compared with no therapy or medical therapy, with no significant decrease in mortality or bronchopulmonary dysplasia.[80]Mosalli R, Alfaleh K. Prophylactic surgical ligation of patent ductus
arteriosus for prevention of mortality and morbidity in extremely low birth
weight infants. Cochrane Database Syst Rev. 2008;(1):CD006181.
http://www.ncbi.nlm.nih.gov/pubmed/18254095?tool=bestpractice.com
Another review refuted earlier postulations that primary surgical ligation may decrease the incidence of necrotizing enterocolitis.[81]Yee WH, Scotland J; Evidence-based Practice for Improving Quality (EPIQ) Evidence Review Group. Does primary surgical closure of the patent ductus arteriosus in infants <1500 g or ≤32 weeks' gestation reduce the incidence of necrotizing enterocolitis? Paediatr Child Health. 2012 Mar;17(3):125-8.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287088
http://www.ncbi.nlm.nih.gov/pubmed/23449771?tool=bestpractice.com
Videothorascopic surgical ligation is being used with increasing frequency in selected cases with good results.[82]Laborde F, Folliguet TA, Etienne PY, et al. Video-thoracoscopic surgical interruption of patent ductus arteriosus. Routine experience in 332 pediatric cases. Eur J Cardiothorac Surg. 1997 Jun;11(6):1052-5. http://www.ncbi.nlm.nih.gov/pubmed/9237586?tool=bestpractice.com
percutaneous catheter device closure
Transcatheter closure of PDA in preterm and extremely low birth weight infants is becoming more feasible and less complicated with the advent of smaller devices and smaller delivery sheaths. In practice, this is becoming a more common second-line therapy for ductal closure than surgical ligation in most academic centers.[59]Canadian Paediatric Society. Management of the patent ductus arteriosus in preterm infants. Feb 2022 [internet publication]. https://cps.ca/en/documents/position/patent-ductus-arteriosus [61]Backes CH, Hill KD, Shelton EL, et al. Patent ductus arteriosus: a contemporary perspective for the pediatric and adult cardiac care provider. J Am Heart Assoc. 2022 Sep 6;11(17):e025784. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496432 http://www.ncbi.nlm.nih.gov/pubmed/36056734?tool=bestpractice.com
Catheter devices include coils, the Amplatzer duct occluder, the Rashkind umbrella device, and the Gianturco-Grifka occlusion device. Choice of device depends on ductal morphology and operator choice during the procedure.[83]Grifka RG. Transcatheter closure of the patent ductus arteriosus. Catheter Cardiovasc Interv. 2004 Apr;61(4):554-70. Patients are given subacute bacterial endocarditis prophylaxis for 6 months after the procedure, or longer if turbulent flow persists around the device.[84]Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation. 2021 May 18;143(20):e963-78. https://www.doi.org/10.1161/CIR.0000000000000969 http://www.ncbi.nlm.nih.gov/pubmed/33853363?tool=bestpractice.com
term infants and children: small-to-moderate-sized ducts
percutaneous catheter device closure
In asymptomatic or symptomatic patients, percutaneous catheter closure is the first-line treatment to treat heart failure and prevent elevated pulmonary pressures or endarteritis. It avoids surgery and can usually be done with just a day admission or overnight hospital stay. Safe device closure has been reported in patients as young as 6 months and as small as 5 kg.[85]Butera G, De Rosa G, Chessa M, et al. Transcatheter closure of persistent ductus arteriosus with the Amplatzer duct occluder in very young symptomatic children. Heart. 2004 Dec;90(12):1467-70. http://heart.bmj.com/cgi/content/full/90/12/1467 http://www.ncbi.nlm.nih.gov/pubmed/15547030?tool=bestpractice.com With infants who are symptomatic and aged >6 months, percutaneous catheter device closure is carried out as soon as possible. In symptomatic infants ages <6 months, intervention is delayed if possible. In these circumstances, provided that the child is gaining weight adequately, temporary use of diuretic therapy with furosemide can control symptoms and give time for the infant to grow to a more suitable size for percutaneous intervention. Percutaneous catheter device closure is also the first-line treatment in asymptomatic patients, though this is delayed where possible until the patient is ages ≥1 year. In children ages >1 year, the procedure can be scheduled at the time of diagnosis, either electively or as needed, depending on their symptoms and left heart overload.
The procedure has an extremely high success rate of >95% with no mortality and few complications.[87]Masura J, Tittel P, Gavora P, et al. Long-term outcome of transcatheter patent ductus arteriosus closure using Amplatzer duct occluders. Am Heart J. 2006 Mar;151(3):755.e7-755.e10. http://www.ncbi.nlm.nih.gov/pubmed/16504649?tool=bestpractice.com [88]Magee AG, Huggon IC, Seed PT, et al. Transcatheter coil occlusion of the arterial duct; results of the European Registry. Eur Heart J. 2001 Oct;22(19):1817-21. http://eurheartj.oxfordjournals.org/cgi/reprint/22/19/1817 http://www.ncbi.nlm.nih.gov/pubmed/11549304?tool=bestpractice.com Complications can include coil embolization, persistent turbulent flow around the device, and residual leak.[88]Magee AG, Huggon IC, Seed PT, et al. Transcatheter coil occlusion of the arterial duct; results of the European Registry. Eur Heart J. 2001 Oct;22(19):1817-21. http://eurheartj.oxfordjournals.org/cgi/reprint/22/19/1817 http://www.ncbi.nlm.nih.gov/pubmed/11549304?tool=bestpractice.com [89]Al-Ata J, Arfi AM, Hussain A, et al. The efficacy and safety of the Amplatzer ductal occluder in young children and infants. Cardiol Young. 2005 Jun;15(3):279-85. http://www.ncbi.nlm.nih.gov/pubmed/15865830?tool=bestpractice.com Complications are more likely to occur in smaller children.[89]Al-Ata J, Arfi AM, Hussain A, et al. The efficacy and safety of the Amplatzer ductal occluder in young children and infants. Cardiol Young. 2005 Jun;15(3):279-85. http://www.ncbi.nlm.nih.gov/pubmed/15865830?tool=bestpractice.com There are several types of devices that can be employed for catheter closure and choice of device usually depends on the morphology of the duct.[83]Grifka RG. Transcatheter closure of the patent ductus arteriosus. Catheter Cardiovasc Interv. 2004 Apr;61(4):554-70.
Catheter devices include coils, the Amplatzer duct occluder, the Rashkind umbrella device, and the Gianturco-Grifka occlusion device. Choice of device depends on ductal morphology and operator choice during the procedure.[83]Grifka RG. Transcatheter closure of the patent ductus arteriosus. Catheter Cardiovasc Interv. 2004 Apr;61(4):554-70. Patients are given subacute bacterial endocarditis prophylaxis for 6 months after the procedure, or longer if turbulent flow persists around the device.[84]Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation. 2021 May 18;143(20):e963-78. https://www.doi.org/10.1161/CIR.0000000000000969 http://www.ncbi.nlm.nih.gov/pubmed/33853363?tool=bestpractice.com
diuretics
Treatment recommended for SOME patients in selected patient group
Infants who are symptomatic may not be large enough to undergo percutaneous device closure at the time of presentation. In these circumstances, provided that the child is gaining weight adequately, temporary use of diuretic therapy with furosemide can control symptoms and give time for the infant to grow to a more suitable size for percutaneous intervention.
Primary options
furosemide: 0.5 to 2 mg/kg intravenously every 6-12 hours
term infants and children: large ducts and/or symptomatic infants too small for device closure
surgical ligation
Some patent ducts are too large to be closed by a percutaneous catheter device, yet closure is required either to treat or prevent heart failure from the left to right shunt or to prevent endarteritis. This may be recognized at initial workup or when an attempted device closure is made.
If the patient is symptomatic, surgical ligation is undertaken as soon as possible. If asymptomatic, ligation can be scheduled electively. Success is high with few complications that can include operative pneumothorax, hemorrhage, effusion, or long-term recanalization.[75]Koehne PS, Bein G, Alexi-Meskhishvili V, et al. Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment. J Perinat Med. 2001;29(4):327-34. http://www.ncbi.nlm.nih.gov/pubmed/11565202?tool=bestpractice.com [77]Lee LC, Tillet A, Tulloh R. Outcome following patent ductus arteriosus ligation in premature infants: a retrospective cohort analysis. BMC Pediatr. 2006 May 11;6:15. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16689986 http://www.ncbi.nlm.nih.gov/pubmed/16689986?tool=bestpractice.com
With increased percutaneous device closure experience, smaller and younger children are being taken to the catheterization laboratory, so referral for surgical ligation is decreasing in infants younger than 6 months, although this is dependent on institution.[85]Butera G, De Rosa G, Chessa M, et al. Transcatheter closure of persistent ductus arteriosus with the Amplatzer duct occluder in very young symptomatic children. Heart. 2004 Dec;90(12):1467-70. http://heart.bmj.com/cgi/content/full/90/12/1467 http://www.ncbi.nlm.nih.gov/pubmed/15547030?tool=bestpractice.com [90]Fischer G, Stieh J, Uebing A, et al. Transcatheter closure of persistent ductus arteriosus in infants using the Amplatzer duct occluder. Heart. 2001 Oct;86(4):444-7. http://heart.bmj.com/cgi/content/full/86/4/444 http://www.ncbi.nlm.nih.gov/pubmed/11559687?tool=bestpractice.com
adults
percutaneous catheter device closure
In certain adults with patent ductus arteriosus (PDA), closure may be necessary if there is significant left to right shunt and/or pulmonary hypertension. Surgical or catheter-based closure is recommended, provided that pulmonary vascular resistance is not prohibitively high.[91]Fisher RG, Moodie DS, Sterba R, et al. Patent ductus arteriosus in adults--long-term follow-up: nonsurgical versus surgical treatment. J Am Coll Cardiol. 1986 Aug;8(2):280-4. http://www.ncbi.nlm.nih.gov/pubmed/2942590?tool=bestpractice.com [92]Marelli A, Beauchesne L, Colman J, et al. Canadian Cardiovascular Society 2022 guidelines for cardiovascular interventions in adults with congenital heart disease. Can J Cardiol. 2022 Jul;38(7):862-96. https://www.onlinecjc.ca/article/S0828-282X(22)00260-4/fulltext http://www.ncbi.nlm.nih.gov/pubmed/35460862?tool=bestpractice.com Currently, most advocate closure via a transcatheter device in adults with a small to moderate patent ductus; this has been shown to be safe and effective in this population.[93]Hong TE, Hellenbrand WE, Hijazi ZM, et al. Transcatheter closure of patent ductus arteriosus in adults using the Amplatzer duct occluder: initial results and follow-up. Indian Heart J. 2002 Jul-Aug;54(4):384-9. http://www.ncbi.nlm.nih.gov/pubmed/12462665?tool=bestpractice.com [94]Pas D, Missault L, Hollanders G, et al. Persistent ductus arteriosus in the adult: clinical features and experience with percutaneous closure. Acta Cardiol. 2002 Aug;57(4):275-8. http://www.ncbi.nlm.nih.gov/pubmed/12222696?tool=bestpractice.com
Catheter devices include coils, the Amplatzer duct occluder, the Rashkind umbrella device, and the Gianturco-Grifka occlusion device. Choice of device depends on ductal morphology and operator choice during the procedure.[83]Grifka RG. Transcatheter closure of the patent ductus arteriosus. Catheter Cardiovasc Interv. 2004 Apr;61(4):554-70. Patients are given subacute bacterial endocarditis prophylaxis for 6 months after the procedure, or longer if turbulent flow persists around the device.[84]Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation. 2021 May 18;143(20):e963-78. https://www.doi.org/10.1161/CIR.0000000000000969 http://www.ncbi.nlm.nih.gov/pubmed/33853363?tool=bestpractice.com
surgical ligation
In certain adults with PDA, closure may be necessary if there is significant left to right shunt and/or pulmonary hypertension. Concerns regarding ductal tissue friability in adults with larger patent ductus have led some centers to pursue video-assisted thoracic surgery (VATS) ligation, with good results.[95]Yilmaz AT, Yorulmaz FM, Ozturk OY, et al. Ligation in adult persistent ductus arteriosus. J Cardiovasc Surg (Torino). 1991 Sep-Oct;32(5):575-80. http://www.ncbi.nlm.nih.gov/pubmed/1939318?tool=bestpractice.com
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer